01 9Esbriet
02 5Pirespa
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2019 Revenue in Millions : 58
2018 Revenue in Millions : 56
Growth (%) : 3
Main Therapeutic Indication : Immunology
Currency : USD
2019 Revenue in Millions : 1,163
2018 Revenue in Millions : 1,062
Growth (%) : 10
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 55
2019 Revenue in Millions : 59
Growth (%) : -6
Main Therapeutic Indication : Immunology
Currency : USD
2020 Revenue in Millions : 1,235
2019 Revenue in Millions : 1,258
Growth (%) : -2
Main Therapeutic Indication : Immunology
Currency : USD
2021 Revenue in Millions : 1,118
2020 Revenue in Millions : 1,174
Growth (%) : -6
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 35
2020 Revenue in Millions : 53
Growth (%) : -28
Main Therapeutic Indication : Immunology
Currency : USD
2022 Revenue in Millions : 785
2021 Revenue in Millions : 1,118
Growth (%) : -30
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2022 Revenue in Millions : 22
2021 Revenue in Millions : 35
Growth (%) : -39
Main Therapeutic Indication : Immunology
Currency : USD
2023 Revenue in Millions : 234
2022 Revenue in Millions : 785
Growth (%) : -72
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2023 Revenue in Millions : 14
2022 Revenue in Millions : 22
Growth (%) : -25
LOOKING FOR A SUPPLIER?